

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# ClouDr Group Limited

## 智雲健康科技集團\*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9955)**

### INSIDE INFORMATION POSITIVE PROFIT ALERT FOR THE SIX MONTHS ENDED JUNE 30, 2023

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Directors**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and the potential investors that based on the preliminary assessment of the unaudited consolidated management accounts for the six months ended June 30, 2023 (the “**Period**”) of the Company (the “**Management Accounts**”), as well as other relevant information currently available to the Board, the Group expects that its adjusted net loss (non-IFRS measure) for the six months ended June 30, 2023 may be narrowed to between approximately RMB56 million and RMB65 million, representing a decrease of approximately 60% as compared to the adjusted net loss (non-IFRS measure) of RMB148.0 million for the corresponding period in 2022.

1 We define “adjusted net loss (non-IFRS measure)” as loss for the relevant period and adding back (i) change in fair value of financial liabilities, (ii) share-based compensation expenses, (iii) listing expenses, and (iv) issuance cost of financial liability at fair value through profit or loss.

Based on information currently available to the Company, the expected significant year over year decrease in the adjusted net loss (non-IFRS measure) for the Period is primarily attributable to (1) the strong and continued business growth as a result of the virtuous cycle established through our hospital-first strategy and SaaS and AI-powered solutions, which led to the expansion of the Group's network of hospitals and pharmacies, and (2) the continuously improved operating leverage as a result of the unique business model, the established reputation and network in the industry, and high customer stickiness with high recurring purchases.

As at the date of this announcement, the Company is still in the process of finalizing the interim results of the Group for the Period. The information contained in this announcement is therefore only based on a preliminary review of the Management Accounts and other relevant information currently available to the Board. Such Management Accounts have neither been reviewed nor audited by the Company's independent auditor, nor reviewed by the audit committee of the Company. As such, the actual interim results of the Group for the six months ended June 30, 2023 may be different from what is disclosed in this announcement. Shareholders and potential investors are therefore advised to read carefully the interim results announcement of the Company for the six months ended June 30, 2023, which is expected to be published in August, 2023.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**ClouDr Group Limited**  
**Kuang Ming**  
*Chairman, Executive Director and  
Chief Executive Officer*

Hong Kong, August 14, 2023

*As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.*

\* *For identification purpose only*